INTRODUCTION
decrease of inflammation due to a substantial reduction in leukocyte number and/or a decrease in the level of pro-inflammatory cytokines in the BALF and in lung tissue. [21, 22] The aim of this study was to elucidate for the first time expression and inflammatory properties of ET-1 in HASMCs. To this end, we investigated ET-1 expression in response to TNFα stimulation. Since secreted inflammatory factors have been known to temporarily induce their own expression to rapidly potentiate inflammation (autoregulatory positive feedback mechanism), we investigated the auto-regulation of ET-1 expression in cultured HASMCs. We studied the release of GM-CSF in response to TNFα and ET-1. To elucidate the anti-inflammatory properties of Bosentan in HASMCs, we studied its effect on the TNFα/ET-1/GM-CSF network. Finally, we investigated the impact of endothelin receptorsubtypes and mitogen-activated protein-(MAP) kinase pathways in these processes.
METHODS

Isolation and cultivation of HASMCs
HASMCs were dissected from lobar or main bronchus tissue obtained from patients undergoing lung resection as previously described. [23] Cultivation and characterization of HASMCs was performed as described elsewhere. [24] For details see the Supplementary Online Material.
Stimulation of HASMCs
Before stimulation, sub-confluent cell monolayers were deprived from serum for 24 hours as previously described. [24] Details for the media used for serum withdrawal and stimulation are given in the Supplementary Online Material. HASMCs were stimulated with ET-1 (Sigma, Hamburg, Germany; cat#-E7764) at 100nM or with human TNFα (R&D systems, Minneapolis, MN, USA; cat#-210-TA) at 20ng/ml for times as indicated. Bosentan (Actelion Pharmaceuticals, Freiburg, Germany), BQ123 (Sigma; cat#-B150) or BQ788 (Sigma; cat#-B157) were added at 10 -6 M or indicated concentrations 60 or 120 minutes before ET-1 or TNFα-stimulation, respectively. Pre-treatment with monoclonal blocking antibodies to TNFR1 (clone H398; Alexis, Lausen, Switzerland; cat#-ALX-804-200) and TNFR2 (clone 80M2; Alexis; cat#-ALX-804-450) each at 10µg/ml or with PD098059 (10µM; Calbiochem/VWR, Darmstadt, Germany; cat#-513000) and SB203580 (10µM, Calbiochem/VWR; cat#-559389) was done 60 or 30 min before stimulation, respectively.
Semi-quantitative RT-PCR
RNA was isolated with the RNeasy spin column chromatography (Qiagen, Hilden, Germany) according to the instructions of the manufacturer. Semi-quantitative RT-PCR for ET-1 and GM-CSF (with PCR cycle conditions to analyze the output in the linear range) was performed as described before. [25] GAPDH was used as a standard. PCR conditions and primer sequences are given in the Supplementary Online Material.
ELISA
Quantitative enzyme-linked immunosorbent assays (ELISA) for GM-CSF, ET-1 or big-ET-1 were done with supernatants of sub-confluent HASMCs on a 6-well plate. Intracellular ELISA for phosphorylated (active) p38 MAPK with total p38 MAPK as a reference was carried out on sub-confluent HASMCs on a 96-well plate. GM-CSF ELISA was performed as described before. [26] ET-1, big-ET-1 (Biomedica, Vienna, Austria; cat#-BI-20052; cat#-BI-20082) and phosphorylated-p38 MAPK ELISA (R&D Systems; cat#-KBC869)
were performed according to the instructions of the manufacturer. ELISA protocols are given in the Supplementary Online Material.
Western blotting
Protein extraction from HASMCs and immunodetection of phosphorylated (active) ERK-1/-2 and of GAPDH was performed as previously described. [24] Details are given in the Supplementary Online Material.
Statistical analysis
Statistical analyses were performed to examine the effects of TNFα and ET-1 alone or in combination with enzyme-inhibitors on gene transcription, enzyme activation and cytokine release by HASMCs. The Gaussian distribution for each data set was confirmed by histogram analyses and Kolmogorov-Smirnov-test. Results are expressed as mean ± SEM. Comparisons over time or across different stimulations on matched HASMC samples of one subject for n independent subjects were analysed by One-way repeated measures ANOVA with 95% confidence intervals. For separate comparisons of each stimulation post-hoc Bonferroni-Holm tests were performed. A p-value below 0.05 was considered as statistically significant.
RESULTS
ET-1 induces its own expression in HASMCs via ET A R and p38
MAPK
In dose-and time-response experiments ET-1 induced its own transcription in HASMCs at the highest level (about 3-fold above unstimulated control) at 100nM after two hours of stimulation (Fig. 1A,B) . These conditions were used in the further experiments. Notably, the ET-1-inducing effect on ET-1 transcription was maintained for eight hours (Fig.  1B) . A minimum concentration of 10 -6 M of Bosentan was required to block ET-1-induced ET-1 transcription almost completely (Fig. 1C) . ET-1 induced the release of big-ET-1 (the inactive ET-1 precursor) after three to eight hours of stimulation, and this effect was completely blocked by pre-treatment with Bosentan ( Fig. 1D,E) . ET-1-induced ET-1 transcription was completely blocked by BQ123, a highly selective ET A R inhibitor, [15, 27] but not by BQ788 (Fig. 1F,G) , a highly selective ET B R inhibitor, [15, 27] demonstrating a predominant role of ET A R in this process.
ET-1 at 1, 10 (data not shown) and 100nM ( Fig. 2A ) rapidly activated ERK-1/-2 after five to 30 minutes of stimulation in a concentration-independent manner. ET-1 transiently activated p38
MAPK with four peak levels: after five to 30 minutes, two, four and 6.5 hours of stimulation (Fig. 2B) . ET-1-induced ERK-1/-2 and p38 MAPK activation were almost completely impaired by pre-treatment with Bosentan (Fig. 2C,D) . In contrast to PD098059, a specific inhibitor of the ERK-1/-2 pathway, the p38 MAPK -specific inhibitor SB203580 almost completely inhibited ET-1-induced ET-1 transcription (Fig. 2E ). These data provide evidence for an ET A R-and p38 MAPK -dependent ET-1 autoregulatory positive feedback loop in HASMCs.
This hypothesis was supported by the following data: the exogenously added ET-1 was not detectable in the supernatant anymore after two hours of stimulation, however, we detected ET-1 four hours after stimulation ( Supplementary Fig. 1 ), indicating ET-1 de novo synthesis. Post-incubation with Bosentan three hours after ET-1 stimulation reduced both, the release of big-ET-1 after eight hours of ET-1 stimulation and the four-hour p38 MAPK activation peak (Fig. 1E, 2D ). We conclude that the four-hour peak level results from the reactivation of p38 MAPK through de novo synthesized ET-1 and contributes to the big-ET-1 expression observed after eight hours of stimulation and thus to the maintenance of big-ET-1 release (for a detailed discussion see Supplementary Online Material).
ET-1 induces GM-CSF expression via ET A R, ET B R, ERK-1/-2 and p38
MAPK signalling In dose-and time-response experiments ET-1 induced GM-CSF transcription in HASMCs at the highest level (5 to 8-fold above unstimulated control) at 100nM after four hours of stimulation (Fig. 3A,B) . Notably, the inducing effect on GM-CSF transcription was detected at two to eight hours of stimulation (Fig. 3B) . As individual treatments with Bosentan, BQ123, BQ788, PD098059 and SB203580 all abolished ET-1-induced GM-CSF transcription (Fig. 3C-F) we conclude that ET-1 induces GM-CSF expression via ET A R, ET B R, ERK-1/-2 and p38 MAPK signalling.
TNFα induces ET-1 expression via ET A R and p38
MAPK
TNFα did not influence ET-1 mRNA levels at 1ng/ml (data not shown). However, at 10ng/ml (data not shown) and 20ng/ml TNFα (Fig. 4A ) strongly induced ET-1 transcription after two to eight hours of stimulation without statistically significant differences between these concentrations and times. This effect was reduced by specific blocking of TNFR1 or TNFR2 (Fig. 4B) . TNFα induced ET-1 release from HASMCs after four to 72 hours of stimulation (Fig. 4C) . Surprisingly, TNFα-induced ET-1 transcription after four hours and ET-1 release after six hours were both partially blocked by Bosentan (Fig. 4D,E) . TNFα-induced ET-1 transcription was also reduced by BQ123 but not by BQ788 (Fig. 4F,G) .
TNFα activated ERK-1/-2 at 1, 20 and 50ng/ml (Fig. 5A , data not shown) after five to 30 minutes of stimulation in a concentration-independent manner. TNFα activated p38
MAPK at three time-peaks: after five to 45 minutes, five and nine hours of stimulation (Fig. 5B) . Bosentan did not significantly reduce ERK-1/-2-or p38 MAPK activation in response to 15 min TNFα-stimulation (data not shown). TNFα-induced ET-1 transcription was almost completely blocked by SB203580 (Fig. 5C ) but not by PD098059 (data not shown). Thus, our data demonstrate that TNFα-induced ET-1 transcription depends on ET A R and p38 MAPK signalling.
TNFα induces GM-CSF release via activation of endothelin signalling
TNFα induced GM-CSF transcription at two peak levels: after two and eight to twelve hours of stimulation (Fig. 6A) . Whereas the two-hour peak was completely reduced by specific blocking of TNFR1 but not of TNFR2 blockade, the eight-hour peak was partially reduced by individual blocking of both receptor subtypes (Fig. 6B,C) . Bosentan did not modulate GM-CSF transcription after two hours of TNFα stimulation, however, the drug clearly impaired the induction of GM-CSF transcription after eight hours of TNFα stimulation (Fig. 6D) . Both BQ123 and BQ788 individually blocked TNFα-induced GM-CSF transcription after eight hours with a similar efficiency as Bosentan (Fig. 6E,F ). This indicates that unlike the short-term effect the long-term effect of TNFα on GM-CSF expression depends on the activation of each endothelin receptor subtypes.
TNFα induced a strong GM-CSF release after 72 hours, and this effect was reduced by about 65% by Bosentan (Fig. 6G ). TNFα-induced GM-CSF release was also partially reduced by PD098059 and completely impaired by SB203580 (Fig. 6G) . The combined treatment of TNFα-stimulated HASMCs with Bosentan and PD098059 did not result in an additional reduction of GM-CSF expression compared to the individual treatments (Fig. 6G ). These data demonstrate that TNFα-induced GM-CSF release is mediated by ERK-1/-2-and p38
MAPKsignalling and depends, at least in part, on endothelin receptor activity.
DISCUSSION
We found that ET-1 rapidly induces its own expression in HASMCs suggesting an ET-1 autoregulatory positive feedback loop (Fig. 7) . In contrast to blocking ET B R and ERK-1/-2, inhibiting ET A R and p38 MAPK -activity almost completely impaired ET-1-induced ET-1 transcription demonstrating that activation of the ET A R/p38 MAPK -pathway is necessary to initiate and/or maintain this ET-1 feedback mechanism (for further discussion see the Supplementary Online Material). The induction of GM-CSF expression by ET-1 has been described for other cell types, e.g. lung fibroblasts, [16] but we were first able to demonstrate this ET-1-effect in HASMCs thereby underlining ET-1 pro-inflammatory functions. In contrast to ET-1 auto-regulation, its effect on GM-CSF transcription depends on the activation of both endothelin receptor subtypes and on p38
MAPK and ERK-1/-2 pathways. Individual ET A R or ET B R blockade is sufficient to impair ET-1-induced GM-CSF transcription by about 75% or 50%, respectively, indicating that the combined activation of both receptor subtypes is required for maximum effects.
Here, we demonstrate for the first time that TNFα induces rapid ET-1 transcription and release by HASMCs. In a rat model of airway inflammation increased ET-1 release in the lungs was observed after three hours of provocation prior to the main inflammatory response. [28] Since both, TNFα and ET-1 are suggested as initial cytokines in airway inflammation, [7, 28] ET-1 release by HASMCs in response to TNFα might be an initial event in the amplification of inflammation in the airways. Mechanistic insights have been described for cerebrovascular endothelial cells, where the effect of TNFα on ET-1 mRNA up-regulation depends on the generation of reactive oxygen species and on the activation of ERK-1/-2, p38
MAPK and their common downstream target mitogen-and stress-activated protein kinase (MSK). [29] Consistently, we have shown here the complete reduction of TNFα-induced ET-1 transcription by a p38 MAPK -specific inhibitor, but, in contrast, that experimental blocking of ERK-1/-2 has no effect. This indicates that TNFα activates ET-1 transcription in HASMCs via the p38 MAPK /MSK rather than the ERK/MSK pathway. However, our data cannot rule out a MSK-independent signalling mechanism. It has previously been described that TNFα-induced GM-CSF release from HASMCs depends on the activation of the c-jun N-terminal kinase pathway. [23] We have extended these studies by demonstrating that ERK-1/-2 or p38 MAPK blockade also impairs TNFα-induced GM-CSF release suggesting that all three prominent pro-inflammatory MAP-kinase pathways are substantially involved in this process. We showed that TNFα induces GM-CSF transcription at two peak levels after two and eight to twelve hours of stimulation. While the short-term effect exclusively depends on TNFR1, both TNFα receptor subtypes mediate the long-term effect and -notably -also TNFα-induced ET-1 expression, indicating a link between these two signalling events. In addition, Bosentan partially inhibited the long-term (but not the short-term) TNFα effect, demonstrating that endothelin receptor activity is necessary to obtain complete induction and/or to maintain the complete level of GM-CSF expression in response to TNFα. Consistently, Bosentan reduced TNFα-induced GM-CSF release from HASMCs.
These observations raise the question of a mechanistic link between TNFα and endothelin receptor activation. Since TNFα induces ET-1 release, and ET-1 induces its own and GM-CSF expression we suggest the following model for the long-term effect of TNFα on GM-CSF expression: TNFα activates the ET-1 autoregulatory positive feedback loop by initial activation of the ET-1 gene via the p38 MAPK pathway. As a consequence, ET-1 autoand/or paracrinally maintains the increased level of ET-1 expression via ET A R and p38 MAPK and concurrently induces the expression and release of GM-CSF via both endothelin receptor subtypes and p38 MAPK and ERK-1/-2 signalling (Fig. 7) . Our data demonstrating that blocking ET A R (but not ET B R) activity attenuates TNFα-induced ET-1 expression strongly support the hypothesis of an activation of the ET-1 feedback loop in response to TNFα (for a detailed discussion see the Supplementary Online Material). In contrast, the short-term TNFα-effect on GM-CSF expression is Bosentan-insensitive and thus independent from endothelin signalling and might include the canonical and rapid activation of MAP-kinases by TNFR1. This hypothesis is supported by our data showing a rapid increase of p38 MAPK -and ERK-1/-2 activity as early as five minutes after TNFα-stimulation.
HASMCs are believed to contribute to the establishment of inflammation in chronic inflammatory airway diseases and lung fibrosis, [1] and our data suggest that this could be mediated by ET-1 and GM-CSF up-regulation in response to pathogenically elevated TNFα levels. Accordingly, the inhibiting effects of Bosentan on the TNFα/ET-1/GM-CSF network in HASMCs suggest therapeutic utility for Bosentan in the treatment of inflammation in chronic inflammatory airway diseases and lung fibrosis particularly in early stages. Maximal TNFα-induced GM-CSF expression requires the activity of both ET A R and ET B R, suggesting that a dual endothelin receptor blocker might be advantageous in therapy over selective blockers. The current study was designed to elucidate a novel signalling pathway with relevance for airway inflammation in order to provide a basis for developing new therapeutic strategies. The efficiency of dual versus selective endothelin receptor antagonists available for therapy in inhibiting the TNFα/ET-1/GM-CSF network or other inflammatory/pro-fibrotic cytokines whose expression is mediated by TNFα/ET-1 has to be deciphered in further studies.
The BUILD-1 study evaluated the efficacy of Bosentan in IPF. Bosentan was associated with a trend toward delayed time to disease progression or death and improvement in qualityof-life, both of which were more pronounced (and reached statistical significance in a post hoc analysis) in a subgroup of patients with biopsy-confirmed IPF diagnosis. [19] These observations are currently being investigated in the BUILD-3 trial. Our data suggest that this beneficial effect of Bosentan might be a result of antagonising airway inflammation associated with the TNFα/ET-1/GM-CSF network. In summary, we demonstrated that TNFα induces GM-CSF release in HASMCs via the activation of an ET-1 autoregulatory positive feedback loop. Moreover, we provided evidence for the anti-inflammatory properties of the dual receptor antagonist Bosentan in HASMCs, and our data predict therapeutic utility for Bosentan in the treatment of chronic inflammatory airway diseases and lung fibrosis in early stages. In this context, treatment with Bosentan might be an auspicious therapy helping to reduce the application of high doses of corticosteroids and other immunmodulatory drugs. Furthermore, treatment with Bosentan in early disease stages might be useful to avoid the induction of pulmonary hypertension as a late and serious complication of chronic inflammatory diseases and lung fibrosis.
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METHODS
Cultivation of HASMCs
HASMCs were maintained in Dulbecco´s modified Eagle medium (DMEM, Invitrogen, Karlsruhe, Germany; cat#-31885-023) with 10% FCS (Sigma; cat#-N-4637), sodium pyruvate (1 mM; Invitrogen; cat#-11360-039), L-glutamine (2 mM; Sigma cat#-G-7513), non-essential amino acids (1%; Invitrogen; cat#-11140-035), penicillin (100 U/ml), streptomycin (100 µg/ml; Sigma; cat#-P-4333), and amphotericin B (1.5 µg/ml; Sigma cat#-A-2942) in a humidified atmosphere at 37° C, 5% CO 2 . Subconfluent cells were passaged with trypsin (0.25%; Sigma; cat#-T-4674) and 1 mM EDTA. HASMCs were used for experiments at passages 2-7. Cells were plated at equal density into 6-well plates. HASMCs were characterized by positive immunostaining for calponin, smooth muscle α-actin, and myosin heavy chain.
Stimulation of HASMCs: Media
Serum withdrawal: serum-free and low glucose (1g/l) DMEM (Invitrogen; cat#-41966-029) supplemented with 1mM sodium pyruvate, 2mM L-glutamine, non-essential amino acids, 100U/ml penicillin, 100µg/ml streptomycin, 1.5µg/ml amphotericin B, 1mM insulin, 5mg/ml apo-transferrin and 100µM ascorbic acid. Stimulation: serum-free and low glucose (1g/l) DMEM supplemented with 1mM sodium pyruvate, 2mM L-glutamine, nonessential amino acids, 100U/ml penicillin, 100µg/ml streptomycin, and 1.5µg/ml amphotericin B.
Semiquantitative RT-PCR (PCR conditions and primer sequences)
PCR conditions for ET-1: denaturation, 94°C, 30 sec; annealing, 61°C, 30 sec; extension, 72°C, 30 sec; 39 cycles; ET-1 forward primer 5´-GAG AGG TCC ATT GTC ATC CCC-3´, ET-1 reverse primer 5´-TGT GGC GAC TCT GCA CTC-3´. PCR conditions for GM-CSF: denaturation, 94°C, 30 sec; annealing, 55°C, 30 sec; extension, 72°C, 30 sec; 35 cycles; GM-CSF-primer pairs were purchased from R&D systems (cat#-RDP-34). PCR conditions for GAPDH: denaturation, 94°C, 45 sec; annealing, 60°C, 45 sec; extension, 72°C, 45 sec; 27 cycles; GAPDH forward primer 5´-TCT AGA CGG CAG GCT AGG TCC ACC-3´, GAPDH reverse primer 5´-ACG GTA CCT TAA ACG GTA CCC ACC-3´.
ELISA protocols
ET-1 ELISA was performed according to the instructions of the manufacturer (Biomedica, Vienna, Austria cat#-BI 20052). Briefly, 50 µl of supernatants together with monoclonal mouse anti-human-endothelin antibody were incubated in 96-wells (coated with polyclonal anti-human ET-1 antibody) for 16 hours at room temperature. Following washing, HRP-coupled anti-mouse IgG was added for one hour at room temperature. After washing, detection was performed with TMB as a substrate and measuring extinction at 450 nm with 620 nm as reference. Quantification was done by interpolation from a standard curve with the lower limit of detection of 0.3 fmol/ml.
Big-ET-1 ELISA (that does not crossreact with ET-1) was performed according to the instructions of the manufacturer (Biomedica; cat#-BI 20082). Briefly, 50 µl of supernatants of HASMC cultures together with HRP-coupled monoclonal mouse anti-human big-ET-1 antibody were incubated in 96-wells (coated with polyclonal sheep anti-human big-ET-1 antibody directed against amino acids 22-38) for 4 hours at room temperature. After washing, detection was performed with TMB as a substrate and measuring extinction at 450 nm with 620 nm as reference. Quantification was done by interpolation from a standard curve with the lower limit of detection of 0.02 fmol/ml. Intracellular ELISA for active p38 MAPK (R&D Systems; cat#-KBC869) on subconfluent HASMCs on a 96-well plate was performed according to the instructions of the manufacturer. This assay is based on the simultaneous detection of phosphorylated (active) p38 MAPK and total p38 MAPK as a reference. Briefly, cells were fixed and lysed with 4% formaldehyde for 20 minutes at room temperature. After washing, fixed cells were treated with quenching buffer (20 minutes at room temperature), and, after additional washing, with 10% fetal bovine serum for blocking (one hour, room temperature). After washing, a mixture of rabbit anti-human-phospho-p38 MAPK (T180/Y182) antibody and mouse anti-human-totalp38 MAPK -antibody was added for 16 hours at 4° C. In order to distinguish between phosphorylated p38
MAPK and the total cellular p38 MAPK content the respective specific antibodies added have to be derived from different species. After washing, a secondary antibody mixture (HRP-conjugated anti-rabbit IgG and AP-conjugated anti-mouse IgG) was added for two hours at room temperature. After washing, HRP-fluorogenic substrate was added for 60 minutes and, afterwards, AP-fluorogenic substrate was added for 5 minutes. Phospho-p38
MAPK was measured using a fluorescence plate reader with excitation at 540 nm and emission at 600 nm, total p38 MAPK was measured with excitation at 360 nm and emission at 450 nm. Values for phospho-p38
MAPK were normalized to values for total p38 MAPK .
Western Blotting
The activation status of ERK-1 and ERK-2 was assessed by Western immunoblot analysis using antibodies that recognize the dual phosphorylated (activated) form of the enzymes. After treatment, HASMCs were lysed in lysis buffer (20 mM Tris base, pH 7.4; 1% Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM NaCl, 5 mM EDTA), supplemented with the proteinase inhibitors PMSF (500 µM), Na-orthovanadate (2 mM), leupeptin (10 µg/ml), aprotinin (25 µg/ml), pepstatin (10 µg/ml), NaF (1.25 mM), and Na-pyrophosphate (1 mM). Insoluble protein was removed by centrifugation at 12,000 x g for 5 min and aliquots of the resulting supernatant were diluted 1:4 in Laemelli buffer (62.5 mM Tris-HCl, 10% v/v glycerol, 1% w/v SDS, 1% β-mercaptoethanol, 0.01% w/v bromophenol blue, pH 6.8) and boiled for 5 min. Denatured proteins (40 µg) were subsequently separated by SDS/PAGE upon 10% vertical slab gels and transferred to Hybond ECL membranes (Amersham, Buckinghamshire, UK) in blotting buffer (Tris base 50 mM, pH 8.3; glycine 192 mM) supplemented with 20% vol/vol methanol. The filter was incubated for 1 h in TBS-Tween-20 (25 mM Tris-base, 150 mM NaCl, pH 7.6 and 0.1% Tween 20, 10% [w/v] nonfat milk and incubated 2 h in TBS-Tween 20 containing 3% BSA and either primary antibodies raised against pERK-1/-2 (Cell Signaling Technology/New England Biolabs, Frankfurt, Germany; cat#-9101) or GAPDH (each diluted 1:1,000). Following 3 x 10-min washes in TBS-Tween 20, the membranes were incubated for 60 min with a goat anti-rabbit peroxidase-conjugated IgG antibody diluted 1:5,000 in TBS-Tween 20 supplemented with 1% nonfat milk for ERK-1/-2, and for 60 min with a rabbit, anti-mouse peroxidase-conjugated IgG antibody diluted 1:4,000 in TBS-Tween 20 supplemented with 5% nonfat milk for GAPDH and then washed again (3 x 10 min). Antibody-labeled proteins were subsequently visualized by enhanced chemiluminescence (Amersham).
signalling but not by ET B R. This raises the question why ET B R activation does not contribute to ET-1 expression? ET-1 binding to its receptors results in the activation of complex intracellular signalling networks that include besides MAP-kinases numerous other signalling pathways, e.g. depending on phospholipase C or Rho kinase. [6, 7] The ET A R-triggered signalling network might contain besides p38 MAPK at least one other, yet unidentified, pathway with a key role for ET-1 gene induction, which, however, is not activated by ET B R. As the differences between the ET A R-and ET B R-triggered signalling networks and targeted transcription factors are not well understood for HASMCs or any other cell type, the mention of candidate pathways would remain highly speculative. Nevertheless, this theory can just as well explain the failure of activated ET B R to induce ET-1 expression as the hypothesis that the p38 MAPK pathway itself might not be associated with ET B R in HASMCs. However, the latter assumption might be rather unlikely as ET B R-dependent p38 MAPK activation has been reported for cell types closely related to HASMCs. [8] Induction of the ET-1 autoregulatory feedback mechanism by TNFα in order to maintain GM-CSF expression. ET-1 release induced by ET-1 itself and by TNFα as well as ET-1-induced GM-CSF transcription all are very rapid processes with measurable outcomes after 2-4 hours of stimulation ( Fig. 1D; 3B ; 4C). A comparable rapid release of de novo synthesised ET-1 in response to TNFα has been demonstrated for cultured rat mesangial cells. [9] The reducing effect of endothelin receptor inhibitors on TNFα-induced GM-CSF transcription in HASMCs after eight hours of stimulation could sufficiently be explained by a cascade of TNFα-induced ET-1 release with subsequent ET-1-induced GM-CSF transcription. However, there are two major arguments for an involvement of the ET-1 feedback mechanism as a substantial part of this cascade maintaining GM-CSF expression. First support is found when matching the ET-1-with the TNFα-induced p38 MAPK activation patterns (compare Fig. 2B with 5B). Besides the expected short-term activation peak (5-45 min) in response to TNFα, p38 MAPK re-activation was observed after five and nine hours of stimulation. Given that TNFα induces (low but measurable) ET-1 release after four and six hours (Fig. 4C) and that initial p38
MAPK activation by ET-1 occurs within five to 30 minutes (Fig. 2B) it is reasonable to suggest that the TNFα-induced five hour p38 MAPK re-activation peak reflects an "initial" p38 MAPK activation through ET-1 that is expressed and released in response to TNFα. Moreover, exogenous ET-1 addition leads to p38 MAPK re-activation via de novo synthesized ET-1 about four hours after initial p38 MAPK activation (Fig. 2B,D) . This time lag matches with the time lag between the five and the nine hour p38 MAPK re-activation peaks in response to TNFα underlining the hypothesis of an induction of the ET-1 autoregulatory positive feedback by TNFα.
Further and strong support for this hypothesis comes from the experiments in Figures  4D-F showing that TNFα-induced ET-1 expression can partially be abolished by ET A R inactivation with BQ123 and by Bosentan. As the literature does not provide any evidence for a direct TNFα/ET A R interaction the only reasonable explanation for the effects of BQ123 and Bosentan is that ET-1 released in response to TNFα-stimulation activates ET A R to further maintain ET-1 expression implying the activation of the ET-1 autoregulatory positive feedback by TNFα. Bosentan already blocks ET-1 release after six hours of TNFα-stimulation (Fig. 4E) and ET-1 can induce GM-CSF transcription within two hours (Fig. 3B) . Thus, a cascade of TNFα-induced ET-1 release with subsequent ET-1-induced ET-1 release and ET-1-induced GM-CSF transcription would also coincide with the long-term effect (eight to twelve hours, Fig. 6A ) of TNFα on GM-CSF transcription. Moreover, the activation of the ET-1 positive feedback mechanism by TNFα can also explain (1) the increasing TNFα-induced ET-1 release for up to 72 hours, and (2) the maintenance of TNFα-induced GM-CSF release over a 48 hour-period (after 24 to 72 hours of stimulation, Fig. 6G ; [10] ).
